Beverly, MA – May 1, 2019 –  LeviSense Medical, Inc. announced that it has successfully raised initial seed funding from ICV Venture Engineering Fund. The funds will be used to acquire and develop technology that will transform the therapeutic bed market and the treatment of complex wounds, also known as decubitus ulcers or pressure injuries. The 2.5 million pressure injury cases a year lead to over 60,000 deaths annually – more deaths than the opioid crisis.

Grade III & IV pressure injuries require months of labor-intensive care to heal and cause an extreme level of patient discomfort. LeviSense’s therapeutic solution offers patients restful, soothing therapy in personalized comfort and reduce caregiver effort.

“This funding will enable us to acquire the exclusive and unrestricted rights to the essential, patented technology and fund further development.  This acquisition moves us much closer to a product solution that will be practical in acute care, skilled nursing, assisted living, and home healthcare settings,” said CEO David Bertoni.

About LeviSense Medical, Inc.:

LeviSense Medical, Inc. is a Boston area medical technology firm engaged in developing a therapeutic bed system that will advance the prevention and treatment of pressure induced wounds and ulcers in a variety of patient populations and disease states.

For more information about LeviSense, visit the company’s Web site at www.LeviSenseMedical.com.

About the ICV Venture Engineering Fund:

ICV has built a community of extraordinary individuals who, by virtue of their wealth, knowledge and caring, can advance corporate responsibility, capitalize businesses at significant levels, and influence systemic and sustainable change in the world.  ICV builds partnerships that can leverage the collective resources of the public, private and nonprofit sectors to solve the most pressing problems that no entity can solve alone.

For more information about ICV, visit the company’s Web site at https://www.icvgroup.org/